Eastgate Biotech CEO Anna Gluskin Talks to 'TheStockRadio.com' About Eastgate's Products and Delivery Technology
(firmenpresse) - WEST CALDWELL, NJ and TORONTO, ON -- (Marketwired) -- 02/08/16 -- EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, announces that its CEO, Anna Gluskin, was interviewed on TheStockRadio.com about their products and delivery technology.
The interview took place on February 1st and is available on TheStockRadio.com website:
"We appreciate the opportunity to discuss our sub-micron delivery technology and its present and potential applications," says Anna Gluskin, EastGate's CEO. "We look forward to introducing the benefits of such delivery, that is now available through our nutraceutical products currently being sold on the market, to a larger audience," continues Gluskin.
TheStockRadio is a small cap research and investment commentary provider. TheStockRadio.com provides a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. They provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on TheStockRadio please visit
TheStockRadio.com Disclosure:
The Stock Radio.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. The website is a service of SeoFreisin, Inc.. Please read our report and visit our website: for complete disclaimer and disclosures.
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Rose Perri
1-647-692-0652
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.02.2016 - 13:30 Uhr
Sprache: Deutsch
News-ID 449221
Anzahl Zeichen: 0
contact information:
Town:
WEST CALDWELL, NJ and TORONTO, ON
Kategorie:
Investment Services & Trading
Diese Pressemitteilung wurde bisher 245 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eastgate Biotech CEO Anna Gluskin Talks to 'TheStockRadio.com' About Eastgate's Products and Delivery Technology"
steht unter der journalistisch-redaktionellen Verantwortung von
EastGate Biotech Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
